Central Venous Line-Related Thrombosis in Children

Acta Haematologica - Tập 115 Số 3-4 - Trang 201-206 - 2006
Shoshana Revel‐Vilk1
1Pediatric Hematology/Oncology Unit, Hadassah Hebrew University Medical Center, Jerusalem, Israel. [email protected]

Tóm tắt

Central venous lines are used in critically ill children and in children with chronic conditions for the administration of intravenous therapy, such as fluids, medications, total parenteral nutrition and blood products. Although the use of central venous lines has greatly improved the quality of care in these children, these catheters may cause serious mechanical, infectious and thrombotic complications. The reported frequency of catheter thrombosis in children is low as 5% in studies including only symptomatic cases and high as 50% in studies where patients are systematically screened for catheter-related thrombosis. The risk factors for catheter-related thrombosis in children are associated with the methods used for catheter insertion and with individual patient characteristics, underlying diagnosis and treatment. The management of catheter-related thrombosis is largely dependent on the requirement of the catheter. If no longer required or nonfunctioning the catheter should be removed. If access is still required and the catheter is functioning, treatment with anticoagulation is recommended in the absence of contraindications. The management of radiographically detected asymptomatic thrombosis in children is less clear. Clinical studies of prophylaxis for catheter-related thrombosis are inconclusive and no definitive recommendations for prophylaxis in adults or in children with central venous thrombosis can be made. Properly designed studies are needed to assess the role of prophylactic anticoagulation for preventing catheter-related thrombosis.

Từ khóa


Tài liệu tham khảo

10.1016%2FS0022-3476%2898%2970149-0

10.1046%2Fj.1538-7836.2003.00308.x

10.1002%2Fcncr.11042

10.1016%2Fjpsu.2003.50168

10.1007%2FPL00014341

10.1016%2FS0022-3476%2896%2970338-4

10.1542%2Fpeds.101.2.e7

10.1002%2Fmpo.10062

10.1067%2Fmpd.2001.111272

10.1055%2Fs-2003-42588

10.1007%2Fs002470050649

10.1053%2Fjpsu.2002.30249

10.1016%2FS0022-3476%2895%2970448-5

10.1097%2F00130478-200101000-00012

10.1016%2FS0022-3476%2898%2970226-4

10.1182%2Fblood.V98.6.1727

10.1111%2Fj.1538-7836.2004.00653.x

10.1183%2F09031936.04.00052504

10.1378%2Fchest.118.6.1598

10.1002%2Fajh.10047

10.1080%2F08880010490457042

10.1159%2F000046591

10.1182%2Fblood-2002-09-2731

10.1016%2FS0022-3476%2897%2970071-4

10.1046%2Fj.1365-2257.1999.00250.x

10.1046%2Fj.1538-7836.2003.00158.x

10.1016%2Fj.thromres.2003.10.008

10.1046%2Fj.1365-2516.2003.00791.x

10.1016%2Fj.amjmed.2003.07.011

10.1182%2Fblood.V99.1.36

10.1001%2Farchinte.163.16.1913

10.1046%2Fj.1445-5994.2002.00171.x

10.1016%2FS0049-3848%2803%2900099-9

10.1016%2FS0959-8049%2897%2989012-0

10.1046%2Fj.1365-2141.1998.00732.x

10.1038%2Fsj.bmt.1702675

10.1097%2F00001721-200107000-00005

10.1007%2Fs00432-003-0528-5

10.1378%2Fchest.113.1.165

10.1007%2FBF01658094

10.1016%2FS0022-3476%2895%2970499-X

10.1007%2Fs001340051289

10.1016%2FS1051-0443%2899%2970239-3

10.1016%2FS0959-8049%2801%2900320-3

10.1080%2F088800102753541323

10.1200%2FJCO.2004.07.019

10.1378%2Fchest.126.3_suppl.645S

10.1097%2F00062752-200309000-00008